133034-00-1

Basic information

• Product Name: 1-(P-TOSYL)-(R)-(-)-3-PYRROLIDINOL 98
• Synonyms: 1-(P-TOSYL)-(R)-(-)-3-PYRROLIDINOL 98;R-1-(p-Tosyl)-3-pyrrolidinol;S-1-Methylpyrrolidin-3-aMine.2HCl;(R)-1-tosylpyrrolidin-3-ol;1-Tosyl-(3S)-hydroxy pyrrolidine;(R)-1-(p-Tosyl)-3-pyrrolidinol,99%e.e.
• CAS NO: 133034-00-1
• Molecular Formula: C₁₁H₁₅NO₃S
• Molecular Weight: 241.309
• Mol File: 133034-00-1.mol

Chemical Properties

• Melting Point: 61-65 °C(lit.)
• Boiling Point: 406.8°Cat760mmHg
• Flash Point: 199.9°C
• Appearance: /
• Density: 1.338g/cm³
• Vapor Pressure: 2.38E-07mmHg at 25°C
• Refractive Index: 1.604
• CAS DataBase Reference: 1-(P-TOSYL)-(R)-(-)-3-PYRROLIDINOL 98(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(P-TOSYL)-(R)-(-)-3-PYRROLIDINOL 98(133034-00-1)
• EPA Substance Registry System: 1-(P-TOSYL)-(R)-(-)-3-PYRROLIDINOL 98(133034-00-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 133034-00-1(Hazardous Substances Data)

Usage

Uses

1. Used in Organic Synthesis:
1-(P-TOSYL)-(R)-(-)-3-PYRROLIDINOL 98 is used as a building block in organic synthesis for its ability to contribute to the formation of complex organic molecules. Its unique structure allows it to be a key component in the synthesis of various compounds, making it a valuable asset in the field of organic chemistry.
2. Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(P-TOSYL)-(R)-(-)-3-PYRROLIDINOL 98 is used as a starting material for the development of new drugs. Its unique properties and reactivity make it a promising candidate for the creation of novel therapeutic agents, potentially leading to the discovery of new medications for various diseases and conditions.
3. Used in Chemical Research:
1-(P-TOSYL)-(R)-(-)-3-PYRROLIDINOL 98 is also utilized in chemical research as a tool to study the properties and reactions of various organic compounds. Its unique structure allows researchers to gain insights into the behavior of different molecules and their interactions, contributing to the advancement of knowledge in the field of chemistry.

InChI:InChI=1/C11H15NO3S/c1-9-2-4-11(5-3-9)16(14,15)12-7-6-10(13)8-12/h2-5,10,13H,6-8H2,1H3/t10-/m1/s1

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 104706-47-0 (R)-3-hydroxypyrrolidine hydrochloride 
• 40499-83-0 (3R)-pyrrolidinol 
• 55022-46-3 4-methyl-N-prop-2-ynylbenzenesulfonamide 

Downstream Products

• 1307881-27-1 (R)-3-sulfamoyloxy-N-(toluene-4-sulfonyl)pyrrolidine 
• 133099-09-9 (S)-diphenyl-[1-(toluene-4-sulfonyl)-pyrrolidin-3-yl]-acetonitrile 

Relevant articles and documents

Rhodium/Yanphos-Catalyzed Asymmetric Interrupted Intramolecular Hydroaminomethylation of trans-1,2-Disubstituted Alkenes

The first interrupted asymmetric hydroaminomethylation reaction was developed. The challenging trans-1,2-disubstituted olefins were employed as substrates, and a series of valuable chiral pyrrolidinones and pyrrolidines were obtained in high yields with high regioselectivities and excellent enantioselectivities. Several synthetic transformations were conducted, demonstrating the high synthetic utility of our method. A creative route for the synthesis of vernakalant and Enablex was also developed.

IMPROVED PROCESS FOR PRODUCING DARIFENACIN

The present invention discloses an improved process for producing darifenacin, the process comprising decarboxylating (2S,4R)-4-hydroxy-2-pyrrolidine carboxylic acid followed by in situ tosylation to give l-tosyl-3-(R)-(-)-hydroxypyrrolidine, tosylating the l-tosyl-3-(R)-(-)-hydroxypyrrolidine with methyl-p-toluenesuolphonate to give l-tosyl-3- (S)-(-)-tosyloxy pyrrolidine, reacting l-tosyl-3-(S)-(-)-tosyloxy pyrrolidine with diphenyl acetonitrile in presence of a base to give 3-(S)-(+)-(l-cyano-l,l-diphenylmethyl)-l- tosylpyrrolidine, de-protecting 3-(S)-(+)-(l-cyano-l,l-diphenylmethyl)-l- tosylpyrrolidine in the presence of phenol in acidic medium to give 3-(S)-(+)-(l-cyano- 1,1-diphenylmethyl) pyrrolidine, hydrolyzing 3-(S)-(+)-(l-cyano-l,l-diphenylmethyl) pyrrolidine followed by salt formation to obtain 3-(S)-(+)-(l-carbamoyl-l,l- diphenylmethyl)pyrrolidine.L-(+)-tartrate, condensing 3-(S)-(+)-( 1 -carbamoyl- 1,1- diphenylmethyl)pyrrolidine-L(+)-tartrate with 5-(2-bromoethyl)-2,3-dihydrobenzofuran employing a base in a solvent to give darifenacin.

PREPARATION OF DARIFENACIN AND ITS SALTS

Provided are various processes and compounds related to darifenacin and/or its salts. For example, there is provided a process for preparing a free base of darifenacin: Formula, or the salt thereof, the process including reacting 3-(S)-(cyanodiphenylmethyl)-1-[2-(2,3-dihydrobenzofuran-5-yl) ethyl] pyrrolidine of the Formula (IV), or a salt thereof: Formula (IV) with a base effective to convert the nitrile group of the compound of the Formula (IV) to the amide group of the darifenacin in an organic solvent, the reaction being carried out in the organic solvent, with a proviso that the solvent is not 2-methyl-butan-2-ol, and with further proviso that the reaction produces less than about 0.5 % of the compound of the Formula (Ic): Formula (Ic) in the reaction mass, as measured by HPLC. Various embodiments and variants are provided.

Muscarinic receptor antagonists

Muscarinic receptor antagonists of formula (I), and their pharmaceutically acceptable salts, wherein Y is --CH 2 --, --(CH 2) 2 --, --CH 2 O--, --(CH 2) 2 O-- or --CH 2 S--; R is --CH or --CONH 2 ; and R 1 is a group of formula (a), where R 2 and R 3 are each independently H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, --(CH 2) n OH, halo, trifluoromethyl, cyano, --(CH 2) n NR 4 R 5, --CO(C 1 -C 4 alkyl), --OCO(C 1 -C 4 alkyl), --CH(OH)(C 1 -C 4 alkyl), --C(OH)(C 1 -C 4 alkyl 2, --SO 2 NH 2, --(CH 2) n CONR 6 R 7 or --(CH 2) n COO(C 1 -C 4 alkyl); R 4 is H or C 1 -C 4 alkyl; R 5 is H, C 1 -C 4 alkyl or C 1 -C 4 alkysulphonyl; R 6 and R 7 are each independently H or C 1 -C 4 alkyl; and n is 0, 1 or 2. The compounds are particularly useful in treating irritable bowel syndrome.